Docetaxel-oxaliplatin-capecitabine/5-fluorouracil (DOX/F) followed by docetaxel versus oxaliplatin-capecitabine/5-fluorouracil (CAPOX/FOLFOX) in HER2-negative advanced gastric cancers.
Anant RamaswamyPrabhat BhargavaBiswajit DubashiAnuj GuptaAkhil KapoorSujay SrinivasOmshree ShettyPoonam JadhavVeena DesaiVanita NoronhaAmit JoshiNandini MenonVijay M PatilBal Krishna MishraBipinesh SansarArpita SinghSwapnil PatelSatyendra Narayan SinghIpsita DhalKunal Ranjan VinayakVikash PalSarika MandavkarSadhana KannanDeepali ChauguleRajshree PatilManali ParulekarChaitali NashikkarSuman Kumar AnkathiRajiv Kumar KaushalAekta ShahPrasanth GanesanSmita KayalRamesh AnanthakrishnanNoorzia SyedDebdeep SamaddarVenkatesh KapuAnokhi ShahD KaaviyaR SuganiyaNirmala Devi SrinivasanKumar PrabhashVikas OstwalPublished in: JNCI cancer spectrum (2024)
FOLFOX or CAPOX chemotherapy for 6 months remains one of the standards of care in advanced HER2-negative gastroesophageal junction and gastric adenocarcinomas, with no additional survival benefit seen with the addition of docetaxel. Genomic profiling of patients revealed a higher than previously known incidence of somatic BRCA alterations, which requires further evaluation.CTRI (Clinical Trial Registry of India: CTRI/2020/03/023944).
Keyphrases
- locally advanced
- metastatic colorectal cancer
- clinical trial
- rectal cancer
- phase ii study
- end stage renal disease
- squamous cell carcinoma
- newly diagnosed
- single cell
- healthcare
- ejection fraction
- phase iii
- radiation therapy
- copy number
- palliative care
- peritoneal dialysis
- randomized controlled trial
- metastatic breast cancer
- gene expression
- quality improvement
- patient reported outcomes
- chronic pain
- genome wide
- free survival
- patient reported
- affordable care act